Literature DB >> 12091365

Keratinocyte growth factor preserves normal thymopoiesis and thymic microenvironment during experimental graft-versus-host disease.

Simona Rossi1, Bruce R Blazar, Catherine L Farrell, Dimitry M Danilenko, David L Lacey, Kenneth I Weinberg, Werner Krenger, Georg A Holländer.   

Abstract

Thymus-dependent reconstitution of the peripheral T-cell compartment is critical for the successful outcome of bone marrow transplantation. However, graft-versus-host disease (GVHD) affects thymic stromal function and thus prevents normal T-cell maturation and selection. To determine whether cytoprotection of thymic epithelial cells (TECs) by keratinocyte growth factor (KGF) averts GVHD-related injury to the thymus, a nonirradiated murine parent-->F(1) transplantation model was investigated. Administration of KGF between days -3 and +3 of GVHD induction preserved normal thymic size, cellularity, and thymocyte phenotype when measured 2 weeks after transplantation and compared with saline-treated parent-->F(1) mice that received allogeneic transplants. Moreover, the characteristic GVHD-induced impairment in cell cycle progression of pro- and pre-T cells was prevented by KGF. However, the normal phenotypic and functional status of the thymus did not correlate with the higher number of GVHD-inducing mature donor T cells in thymi of KGF-treated mice. Importantly, extensive analysis of the different TEC populations within the thymic cortex and medulla revealed an almost normal stromal architecture and composition in GVHD mice treated with KGF. These observations are likely to reflect an indirect effect of KGF on thymopoiesis as KGF-receptor expression was demonstrated to be restricted to TECs. Thus, pharmacologic doses of KGF appear to exert a potent effect on TEC function, which in turn allows for normal T lymphopoiesis to occur during acute GVHD.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12091365     DOI: 10.1182/blood.v100.2.682

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  71 in total

Review 1.  Immune-based therapies: an adjunct to antiretroviral treatment.

Authors:  Jeffrey M Jacobson
Journal:  Curr HIV/AIDS Rep       Date:  2005-06       Impact factor: 5.071

Review 2.  Adoptive precursor cell therapy to enhance immune reconstitution after hematopoietic stem cell transplantation.

Authors:  J L Zakrzewski; A M Holland; M R M van den Brink
Journal:  J Mol Med (Berl)       Date:  2007-02-28       Impact factor: 4.599

3.  Delayed immune reconstitution after cord blood transplantation is characterized by impaired thymopoiesis and late memory T-cell skewing.

Authors:  Krishna V Komanduri; Lisa S St John; Marcos de Lima; John McMannis; Steven Rosinski; Ian McNiece; Susan G Bryan; Indreshpal Kaur; Sean Martin; Eric D Wieder; Laura Worth; Laurence J N Cooper; Demetrios Petropoulos; Jeffrey J Molldrem; Richard E Champlin; Elizabeth J Shpall
Journal:  Blood       Date:  2007-08-01       Impact factor: 22.113

Review 4.  Clinical strategies to enhance T cell reconstitution.

Authors:  Gabrielle L Goldberg; Johannes L Zakrzewski; Miguel A Perales; Marcel R M van den Brink
Journal:  Semin Immunol       Date:  2007-10-26       Impact factor: 11.130

Review 5.  Clinical strategies to enhance posttransplant immune reconstitution.

Authors:  Irwin D Bernstein; Richard L Boyd; Marcel R M van den Brink
Journal:  Biol Blood Marrow Transplant       Date:  2008-01       Impact factor: 5.742

6.  A randomized controlled trial of palifermin (recombinant human keratinocyte growth factor) for the treatment of inadequate CD4+ T-lymphocyte recovery in patients with HIV-1 infection on antiretroviral therapy.

Authors:  Jeffrey M Jacobson; Hongying Wang; Rebeka Bordi; Lu Zheng; Barry H Gross; Alan L Landay; John Spritzler; Jean-Pierre Routy; Constance Benson; Judith Aberg; Pablo Tebas; David W Haas; Jennifer Tiu; Kristine Coughlin; Lynette Purdue; Rafick-Pierre Sekaly
Journal:  J Acquir Immune Defic Syndr       Date:  2014-08-01       Impact factor: 3.731

7.  Inducible expression of keratinocyte growth factor (KGF) in mice inhibits lung epithelial cell death induced by hyperoxia.

Authors:  Prabir Ray; Yvan Devaux; Donna B Stolz; Manohar Yarlagadda; Simon C Watkins; Yunbiao Lu; Li Chen; Xiao-Fang Yang; Anuradha Ray
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-05       Impact factor: 11.205

8.  The cytolytic molecules Fas ligand and TRAIL are required for murine thymic graft-versus-host disease.

Authors:  Il-Kang Na; Sydney X Lu; Nury L Yim; Gabrielle L Goldberg; Jennifer Tsai; Uttam Rao; Odette M Smith; Christopher G King; David Suh; Daniel Hirschhorn-Cymerman; Lia Palomba; Olaf Penack; Amanda M Holland; Robert R Jenq; Arnab Ghosh; Hien Tran; Taha Merghoub; Chen Liu; Gregory D Sempowski; Melissa Ventevogel; Nicole Beauchemin; Marcel R M van den Brink
Journal:  J Clin Invest       Date:  2009-12-01       Impact factor: 14.808

9.  Short-term inhibition of p53 combined with keratinocyte growth factor improves thymic epithelial cell recovery and enhances T-cell reconstitution after murine bone marrow transplantation.

Authors:  Ryan M Kelly; Emily M Goren; Patricia A Taylor; Scott N Mueller; Heather E Stefanski; Mark J Osborn; Hamish S Scott; Elena A Komarova; Andrei V Gudkov; Georg A Holländer; Bruce R Blazar
Journal:  Blood       Date:  2009-12-04       Impact factor: 22.113

Review 10.  Rejuvenation of the aging T cell compartment.

Authors:  Amanda M Holland; Marcel R M van den Brink
Journal:  Curr Opin Immunol       Date:  2009-07-14       Impact factor: 7.486

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.